Growth retardation and tumour inhibition by BRCA1

Jeffrey T. Holt, Marilyn E. Thompson, Csilla Szabo, Cheryl Robiǹson-Benion, Carlos L. Arteaga, Mary Claire King, Roy A. Jensen

Research output: Contribution to journalArticle

369 Scopus citations

Abstract

Inherited mutations in BRCA1 predispose to breast and ovarian cancer, but the role of BRCA1 in sporadic breast and ovarian cancer has previously been elusive. Here, we show that retroviral transfer of the wild-type BRCA1 gene inhibits growth in vitro of all breast and ovarian cancer cell lines tested, but not colon or lung cancer cells or fibroblasts. Mutant BRCA1 has no effect on growth of breast cancer cells; ovarian cancer cell growth is not affected by BRCA1 mutations in the 5' portion of the gene, but is inhibited by 3' BRCA1 mutations. Development of MCF-7 tumours in nude mice is inhibited when MCF-7 cells are transfected with wild-type, but not mutant, BRCA1. Most importantly, among mice with established MCF-7 tumours, peritoneal treatment with a retroviral vector expressing wild-type BRCA1 significantly inhibits tumour growth and increased survival.

Original languageEnglish (US)
Pages (from-to)298-302
Number of pages5
JournalNature genetics
Volume12
Issue number3
DOIs
StatePublished - Mar 1 1996

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'Growth retardation and tumour inhibition by BRCA1'. Together they form a unique fingerprint.

  • Cite this

    Holt, J. T., Thompson, M. E., Szabo, C., Robiǹson-Benion, C., Arteaga, C. L., King, M. C., & Jensen, R. A. (1996). Growth retardation and tumour inhibition by BRCA1. Nature genetics, 12(3), 298-302. https://doi.org/10.1038/ng0396-298